Enterprise Value

509.9M

Cash

37.46M

Avg Qtr Burn

-13.52M

Short % of Float

9.00%

Insider Ownership

7.87%

Institutional Own.

89.81%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Govorestat (AT-007) Details
Galactosemia, Rare genetic disease, Rare diseases

PDUFA

Approval decision

Caficrestat (AT-001) Details
Hemophilia, Genetic disorder, Diabetic cardiomyopathy

Phase 3

Update

Govorestat (AT-007) Details
Sorbitol dehydrogenase deficiency

Phase 3

Update

Govorestat (AT-007) Details
Congenital disorder of glycosylation, Phosphomannomutase 2 deficiency

Phase 2

Update

AT-003 Details
Diabetic retinopathy

Phase 1

Update

AT-104 Details
Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma

Failed

Discontinued